Holen Sie sich die Stockscreener-App
4.52
11.60%
0.47
Handel nachbörslich:
4.47
-0.05
-1.11%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MNKD?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$4.05
Offen:
$4.095
24-Stunden-Volumen:
9.19M
Relative Volume:
1.70
Marktkapitalisierung:
$1.40B
Einnahmen:
$360.78M
Nettoeinkommen (Verlust:
$-23.91M
KGV:
-57.87
EPS:
-0.0781
Netto-Cashflow:
$13.07M
1W Leistung:
+15.01%
1M Leistung:
+31.78%
6M Leistung:
-19.29%
1J Leistung:
+24.86%
1-Tages-Spanne:
$4.08
$4.545
1-Wochen-Bereich:
$3.90
$4.545
52-Wochen-Spanne:
$2.23
$6.51
Mannkind Corp Stock (MNKD) Company Profile
Firmenname
Mannkind Corp
Sektor
Branche
Telefon
818-661-5000
Adresse
1 CASPER STREET, DANBURY, CA
Compare MNKD vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
4.52 | 1.32B | 360.78M | -23.91M | 13.07M | -0.0781 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-27 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-13 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-10-10 | Eingeleitet | Leerink Partners | Outperform |
| 2025-07-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-10 | Eingeleitet | Wedbush | Outperform |
| 2024-12-20 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-10-10 | Eingeleitet | Wedbush | Outperform |
| 2021-05-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | Eingeleitet | Oppenheimer | Outperform |
| 2019-10-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-05-14 | Eingeleitet | BTIG Research | Buy |
| 2019-03-04 | Eingeleitet | SVB Leerink | Outperform |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2018-02-28 | Herabstufung | Maxim Group | Hold → Sell |
| 2017-11-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2017-10-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-10-06 | Bestätigt | Maxim Group | Buy |
| 2017-08-11 | Eingeleitet | Maxim Group | Buy |
| 2016-05-10 | Bestätigt | Piper Jaffray | Underweight |
| 2016-05-10 | Bestätigt | RBC Capital Mkts | Underperform |
| 2016-01-06 | Bestätigt | Piper Jaffray | Underweight |
| 2016-01-06 | Bestätigt | RBC Capital Mkts | Underperform |
| 2015-11-04 | Herabstufung | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | Herabstufung | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-05-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2015-05-11 | Bestätigt | MLV & Co | Hold |
| 2015-04-16 | Bestätigt | RBC Capital Mkts | Outperform |
Alle ansehen
Mannkind Corp Aktie (MNKD) Neueste Nachrichten
5 Best Rising Penny Stocks to Buy According to Wall Street Analysts - Insider Monkey
Is MannKind Corporation (MNKD) A Good Stock To Buy Now? - Yahoo Finance
MannKind Corp (MNKD) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
MannKind shares, Friday focus on the U.S. listing - AD HOC NEWS
MannKind Corp (MNKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Breakthrough T1D backs MannKind’s pediatric Afrezza trial - Stock Titan
MNKD Stock Price, Quote & Chart - ChartMill
MannKind Corp (MNKD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MannKind Corp (MNKD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MannKind Corp (MNKD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MannKind Corp (MNKD) Valuation: PE, PB & Fair Value Analysis - TradingKey
MannKind Corp (MNKD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MannKind Corp (MNKD) Institutional Confidence - TradingKey
MannKind Corp (MNKD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MannKind Corp (MNKD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q1 2026 MannKind Corp Earnings Call Transcript - GuruFocus
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story” - Insider Monkey
MANNKIND CORP (MNKD) Stock Chart - ChartMill
7 Hidden Penny Stocks to Invest In - Insider Monkey
MannKind (MNKD) Stock And Valuation After New Afrezza And FUROSCIX Clinical Data - Yahoo Finance
ADA 2026 data highlight pediatric outcomes and treatment satisfaction with Afrezza - Contemporary Pediatrics
MannKind (MNKD) Stock Price, News & Analysis - MarketBeat
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children - Stocktwits
Jim Cramer Says He Blessed MannKind as a Speculation Only - Insider Monkey
MannKind highlights wider role for Afrezza at ADA 2026 - The Pharma Letter
Jim Cramer Puts This Chip Stock In The 'Penalty Box,' Warns Occidental Could 'Go Down A Lot' If War Ends - Sahm
Jim Cramer Highlighted 16 Stocks Including Quantinuum, and the Market’s Appetite for New Supply - Insider Monkey
MannKind shares more data backing inhaled insulin - Drug Delivery Business
New data affirm safety and efficacy of MannKind's Afrezza inhaled insulin for children and adults with diabetes. - Pluang
MannKind Corporation Presents New Clinical Data Supporting Afrezza and FUROSCIX at ADA 2026 Scientific Sessions - Quiver Quantitative
Inhaled insulin data explore options for kids, pregnancy and pump users - Stock Titan
MannKind (MNKD) Advances Clinical Trials for Inhaled IPF Therapy - Insider Monkey
MannKind Corp stock (US5638651064): focus on valuation metrics after recent FDA and partnership news - AD HOC NEWS
Earnings call transcript: MannKind Q1 2026 sees revenue growth, stock surges - Investing.com
MNKD Stock Heads For Strongest Month In Over Three Years As FDA Catalyst Draws Closer - Stocktwits
Assessing MannKind (MNKD) Valuation After Recent Share Price Momentum And Royalty Growth Expectations - simplywall.st
MannKind develops inhaled ralinepag formulation for United Therapeutics - Investing.com
MannKind Q1 2026 slides: revenue up 15%, three catalysts ahead - Investing.com
MannKind stock surges on United Therapeutics partnership deal - Investing.com
5 Most Promising Penny Stocks According to Wall Street Analysts - Insider Monkey
MannKind (MNKD) Announces Milestones in Nintedanib DPI Development for IPF - GuruFocus
MannKind (MNKD) Announces Milestones in Nintedanib DPI Developme - GuruFocus
MannKind completes patient enrollment in nintedanib DPI trials - Investing.com
MannKind Corporation Advances Nintedanib DPI Program for IPF with Phase 1b INFLO-1 Study Data Expected in Q3 2026 - Quiver Quantitative
MannKind tests inhaled IPF drug in global trial, first data Q3 2026 - Stock Titan
FDA approves MannKind’s Afrezza inhaled insulin for children with diabetes - Investing.com
FDA clears MannKind (NASDAQ: MNKD) Afrezza use in children 6 and older - Stock Titan
MannKind At An Inflection Point: Pediatric Expansion Drives The Story (NASDAQ:MNKD) - Seeking Alpha
MannKind Corp stock (US5638651064): Afrezza pediatric FDA approval and share price weakness draw foc - AD HOC NEWS
Implications of Pediatric Inhaled Insulin Approval - PharmTech.com
Finanzdaten der Mannkind Corp-Aktie (MNKD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Mannkind Corp-Aktie (MNKD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Thomson David | EVP Genl Counsel & Secretary |
May 12 '26 |
Sale |
3.29 |
3,033 |
9,979 |
826,299 |
3.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):